Skip to main content

Table 1 Baseline characteristics between DWI positive and DWI negative group in patients treated with IV tPA

From: In-hospital clinical outcomes in diffusion weighted imaging-negative stroke treated with intravenous thrombolysis

 

Overall

(n = 437)

DWI-negative

(n = 54)

DWI-positive

(n = 383)

P value

Age, yrs. (mean (SD))

62.5 (11.8)

62.1 (9.9)

62.5 (12.1)

0.80

Male, n (%)

320 (73.2)

37 (68.5)

283 (73.9)

0.40

DNT time, min (median [IQR])

45 [35–61]

41.5 [30.5–55]

45 [35–62]

0.06

Time from symptom onset to IV-tPA, min (median [IQR])

168 [128–215]

160 [116–204]

170 [129.5–215.5]

0.16

Time from symptom onset to the first MR scan, hours (median [IQR])

26.0 [19.5–27.6]

26.9 [25.5–27.7]

25.9 [16.0–27.6]

0.03

Bridging mechanical thrombectomy, n (%)

39 (8.9)

0 (0.0)

39 (10.2)

0.01

Pre-mRS score (%)

   

0.26

 0

329 (75.3)

44 (81.5)

285 (74.4)

 

 1

57 (13.0)

9 (16.7)

48 (12.5)

 

 2

26 (5.9)

0 (0.0)

26 (6.8)

 

 3

15 (3.4)

1 (1.9)

14 (3.7)

 

 4

9 (2.1)

0 (0.0)

9 (2.3)

 

 5

1 (0.2)

0 (0.0)

1 (0.3)

 

Admission NIHSS score (median [IQR])

5 [3–9]

2.5 [2–5]

5 [3–9]

< 0.001

Admission NIHSS score ≤ 5, n (%)

248 (56.8)

44 (81.5)

204 (53.3)

< 0.001

NIHSS score at 24 hours (median [IQR])

3 [1–6]

1 [0–2]

3 [1–7]

< 0.001

TOAST, n (%)

   

0.24

 LAA

335 (76.7)

45 (83.3)

290 (75.7)

 

 CE

58 (13.3)

2 (3.7)

56 (14.6)

 

 SAA

15 (3.4)

3 (5.6)

12 (3.1)

 

 Other

8 (1.8)

1 (1.9)

7 (1.8)

 

 Unknown

21 (4.8)

3 (5.6)

18 (4.7)

 

Posterior circulation stroke, n (%)

118 (27.0)

21 (38.9)

97 (25.3)

0.04

Disabling stroke, n (%)

390 (89.2)

32 (59.3)

358 (93.5)

< 0.001

Hypertension, n (%)

233 (53.3)

24 (44.4)

209 (54.6)

0.16

Atrial fibrillation, n (%)

42 (9.6)

3 (5.6)

39 (10.2)

0.28

Diabetes mellitus, n (%)

104 (23.8)

12 (22.2)

92 (24.0)

0.77

Hyperlipidemia, n (%)

45 (10.3)

4 (7.4)

41 (10.7)

0.46

Prior stroke, n (%)

87 (19.9)

12 (22.2)

75 (19.6)

0.65

Coronary artery disease, n (%)

61 (14.0)

8 (14.8)

53 (13.8)

0.85

Prior antiplatelet therapy, n (%)

62 (14.2)

8 (14.8)

54 (14.1)

0.89

Prior statin therapy, n (%)

53 (12.1)

8 (14.8)

45 (11.7)

0.52

Smoking, n (%)

228 (52.2)

22 (40.7)

206 (53.8)

0.07

Drinking, n (%)

190 (43.5)

21 (38.9)

169 (44.1)

0.47

Admission SBP level, mmHg (median [IQR])

150 [137–165]

145 [136.5–155.5]

151 [137–166]

0.06

Admission DBP level, mmHg (median [IQR])

88 [80–97]

86 [78.5–91]

89 [80–98]

0.15

Admission serum glucose level, mmol/L (median [IQR])

6.83 [5.9–8.8]

6.41 [5.5–8.0]

6.89 [5.9–8.8]

0.05

HbA1c level, % (median [IQR])

6 [5.7–6.9]

6 [5.7–6.7]

6 [5.7–6.9]

0.92

LDL level, mmol/L (mean (SD))

2.61 (0.9)

2.42 (0.9)

2.63 (0.9)

0.27

Cholesterol level, mmol/L (mean (SD))

4.19 (1.0)

3.87 (1.0)

4.23 (1.0)

0.08

Fazekas scale, (median [IQR])

1 [1–2]

1 [0–1]

1 [1–2]

0.01

Large vessel occlusion, n (%)

99 (22.7)

3 (5.6)

96 (25.1)

0.01

sICH, n (%)

23 (5.3)

1 (1.9)

22 (5.7)

0.38

  1. DWI Diffusion weighted imaging, DNT Door-to-needle, IV Intravenous thrombolysis, tPA Tissue plasminogen activator, mRS Modified Rankin Scale, NIHSS National institutes of health stroke scale, TOAST Trial of Org 10,172 in Acute Stroke Treatment, LAA Large atherosclerosis artery, CE Cardiac embolism, SAA Small artery occlusion, SBP Systolic blood pressure, DBP Diastolic blood pressure, LDL Low density lipoprotein, sICH Symptomatic intracerebral hemorrhage